Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Solid Neoplasm: early-phase trial registry
94 of 177 indexed Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #62 of 28,707 conditions by registered trial count.
177 US clinical trials · 94 currently recruiting · #62 of 28,707 conditions by registered trial count
Malignant Solid Neoplasm: 177 US clinical trials tracked, 94 recruiting.
Malignant Solid Neoplasm is the subject of 177 registered US clinical trials on ClinicalTrials.gov, 94 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 42 of these trials.
Enrollment posture brief
Registry condition malignant-solid-neoplasm
OPEN 94 | RECR 53% | LATE 14 | EARLY 46 | RANK #62 | SPON 42
Volume-matched condition peers
Nearest open-share peer: Endometriosis (53% recruiting · 49 trials)
Malignant Solid Neoplasm lists 94 open slots (53% of 177 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Solid Neoplasm is recruiting above its size-band peers.
94 of 177 indexed trials (53.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Solid Neoplasm research.
M.D. Anderson Cancer Center accounts for 42 of 177 trials (23.7%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Malignant Solid Neoplasm enrolment sits around 105 participants.
Median target enrolment is 105 among the 177 trials that report a genuine target (sentinel values excluded). 84 of those (47.5%) plan for fewer than 100 participants.
-
Malignant Solid Neoplasm research is mostly interventional.
128 interventional and 49 observational studies make up this index (72.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
177 total, page 3 of 4
Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in Clinical Trials in Minority Patient Populations: Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients
Mayo Clinic
NCT04630431
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
Children's Oncology Group
NCT05228275
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
NCT04905082
Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
Fred Hutchinson Cancer Center
NCT04409236
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
University of Rochester NCORP Research Base
NCT03996265
Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery
City of Hope Medical Center
NCT04596384
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
Children's Oncology Group
NCT04089358
Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer
Fred Hutchinson Cancer Center
NCT05075759
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Children's Oncology Group
NCT03223753
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE
University of Washington
NCT05012124
Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
M.D. Anderson Cancer Center
NCT04650178
Patient Reported Symptom Control With THC or CBD Use
M.D. Anderson Cancer Center
NCT04875286
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
M.D. Anderson Cancer Center
NCT05496972
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT05554367
Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants
M.D. Anderson Cancer Center
NCT03035604
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
NCT02496208
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
M.D. Anderson Cancer Center
NCT04188418
Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors
City of Hope Medical Center
NCT05138991
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
University of Rochester NCORP Research Base
NCT04888988
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT02444741
Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer
M.D. Anderson Cancer Center
NCT05055011
Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic
M.D. Anderson Cancer Center
NCT05102656
Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer
City of Hope Medical Center
NCT05868486
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
Academic and Community Cancer Research United
NCT05246670
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
NCT05286801
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
M.D. Anderson Cancer Center
NCT04296305
Vincristine Pharmacokinetics in Infants
Children's Oncology Group
NCT05359237
Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
Ohio State University Comprehensive Cancer Center
NCT06305884
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
NCT01989585
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
NCT06009926
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
M.D. Anderson Cancer Center
NCT01628029
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02453620
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
M.D. Anderson Cancer Center
NCT02210078
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Thomas Jefferson University
NCT04111172
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
NCT04407247
Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)
M.D. Anderson Cancer Center
NCT02515383
Precision Performance Status Compared With ECOG Performance Status
University of Southern California
NCT07082257
Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians
M.D. Anderson Cancer Center
NCT04196972
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
NCT06136897
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
NCT06351371
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT04940299
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
NCT03449108
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT04459273
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
M.D. Anderson Cancer Center
NCT03168737
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
NCT03878095
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
NCT06360588
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
City of Hope Medical Center
NCT05173961
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
City of Hope Medical Center
NCT05023993
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
OHSU Knight Cancer Institute
NCT03361436
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 22 |
| Phase 3 | 12 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Solid Neoplasm page
177 registered trials, 94 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 94 Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Solid Neoplasm condition card totals 177 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.